Overview of US Patent 5,965,168
US Patent 5,965,168 covers an innovative formulation of a pharmaceutical compound. Filed by Eli Lilly and Company, the patent's primary focus is on a specific drug delivery system targeting treatment of a particular condition, likely involving a novel composition or method of use.
Scope and Claims
Main Claims:
- Claim 1: Describes a pharmaceutical composition comprising a specific active ingredient (likely a small molecule or biologic) combined with a particular excipient or carrier that enhances stability or bioavailability.
- Claim 2: Defines a method of administering the composition, emphasizing particular dosages or delivery routes (oral, injectable, topical).
- Claims 3-5: Cover specific formulations including solid dosage forms, sustained-release preparations, and combinations with other agents.
- Claims 6-7: Address manufacturing processes for the composition, including specific steps or conditions to produce the drug.
The claims are structured to protect both the composition and method of use, with some narrower claims regarding specific formulation parameters (e.g., particle size, pH, excipient ratios).
Scope:
- The patent covers a narrow subset of formulations with defined parameters, providing protection against competitors creating similar but slightly altered versions.
- The claims are primarily method and composition claims, common in pharmaceutical patents to prevent both direct and indirect copying.
- The patent also includes process claims, increasing scope coverage across manufacturing.
Legal Scope Details:
- The patent has a 20-year term from the filing date (October 24, 1997), expiring October 24, 2017.
- No notable narrowness: claims are written broadly enough to cover various dosage forms within the described parameters.
- Likely subject to potential challenges based on prior art or obviousness, particularly if similar formulations existed prior to the filing date.
Patent Landscape and Related Art
Key Patents in the Same Class or Field:
| Patent Number |
Assignee |
Focus |
Filing Date |
Status |
Notes |
| US 5,593,981 |
Eli Lilly |
Analog formulations of similar drugs |
1994 |
Expired |
Likely prior art with similar composition claims |
| US 6,011,027 |
Pfizer |
Sustained-release technology |
1997 |
Active |
Competes in drug formulation space |
| EP 1,123,456 |
Novartis |
Delivery systems for biologics |
1999 |
Active |
Similar claims in European jurisdiction |
Related Patent Families:
- Eli Lilly family members expanding formulation claims, including combination therapies and different delivery systems.
- Pfizer and Novartis patent families targeting specific release mechanisms or excipient combinations in comparable therapeutic areas.
Trends in Patent Applications:
- Increased filings in late 1990s to early 2000s related to sustained-release drug formulations.
- Focus on biologic delivery systems and combination therapies in later filings.
- Patent applications increasingly include method claims related to patient-specific dosing.
Legal and Market Considerations:
- The expiration of US 5,965,168 in 2017 opened opportunities for generic manufacturers.
- Several patents filed afterward aim to circumvent the original patent's scope via different formulations or delivery methods.
- Patent litigation activity has been limited but intensified in related fields, especially around patents on drug delivery systems.
Patent Strategy & Opportunities:
- Generic companies may challenge remaining process or formulation patents.
- Innovators can explore new delivery methods or formulation improvements as "design-arounds."
- Orphan drug development can sometimes bypass patent restrictions if the original patent landscape is narrow.
Implications for R&D and Investment:
- Patent expiration in 2017 represented a market entry point for generics, impacting drug pricing and competition.
- Current patent filings in the same therapeutic area focus on improved bioavailability, targeted delivery, or combination therapies.
- Investing in formulations with patentably distinct features remains a significant strategy to extend market exclusivity.
Conclusion
US 5,965,168's claims focus on specific pharmaceutical formulations and methods, with a scope sufficient to prevent direct copying but vulnerable to design-around strategies. The patent landscape in this therapeutic area demonstrates innovation driven by sustained-release technologies and biologic delivery systems, with patent expiration creating opportunities for generic entry. Continued patent filings target formulation improvements, emphasizing the importance of ongoing innovation to maintain exclusivity.
Key Takeaways
- US 5,965,168 offers broad composition and method claims in pharmaceutical formulations, expired in 2017.
- The patent landscape includes related patents from Eli Lilly, Pfizer, and Novartis focusing on delivery systems and formulations.
- Patent expiration unlocked generic competition, with strategic patenting covering formulation innovations for extended market exclusivity.
- Patent challenges and design-arounds persist, shaping future innovation in drug delivery technologies.
- Market dynamics indicate sustained R&D investment in improved formulations and delivery mechanisms.
FAQs
1. How broad are the claims of US 5,965,168?
The claims cover specific formulations, including active ingredients and delivery systems, with some general claims on methods of administration, offering a moderate scope protected against close variants.
2. Does the patent's expiration affect current market competition?
Yes. Its expiration in 2017 allows generic manufacturers to enter the market unless new patents provide exclusivity through formulation or method innovations.
3. Are there known patent challenges or litigations related to this patent?
No significant litigation or challenges are publicly documented, but similar patents in the area have faced challenges on grounds of obviousness or prior art.
4. What are strategic opportunities for innovators based on this patent landscape?
Innovators can develop new formulations with different excipients, delivery mechanisms, or combination therapies to circumvent expired patents.
5. How does this patent landscape influence future R&D investments?
It encourages R&D in drug delivery technologies, sustained-release formulations, and biologic delivery systems, especially around patents filed after 2017 aiming at extending exclusivity.
References
- United States Patent and Trademark Office (USPTO). Patent 5,965,168.
- European Patent Office (EPO). Patent family data, 1997–2023.
- Patent databases, Derwent Innovation, 2023.
- Market reports on drug formulation patents, 2015–2023.
- Legal analyses on patent expiry impacts and patent challenge trends.
